• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Femtosecond laser update with OptiMedica [VIDEO]

Article

In the following video, Mark Forchette, president and CEO of OptiMedica, discusses how the FDA approval of the Catalys femtosecond laser for creating single-plane and multi-plane arc incisions during cataract surgery, and its subsequent market launch, means to the company.

 

 

In the video, Mark Forchette, president and CEO of OptiMedica, discusses how the FDA approval of the Catalys femtosecond laser for creating single-plane and multi-plane arc incisions during cataract surgery, and its subsequent market launch, means to the company. The discussion continues with Robert P. Rivera, MD, director of clinical research, intraocular lens, and refractive surgery at Hoopes Vision, Draper, UT, offering a clinical perspective of femtosecond laser platforms.

To get more videos from Ophthalmology Times, subscribe to our YouTube channel.

Related Videos
Paul Badawi, co-founder and CEO of Sight Sciences, chats with Neda Shamie, MD, about what drives him
© 2024 MJH Life Sciences

All rights reserved.